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ABSTRACT
We used whole genome microarray analysis to identify potential candidate genes 
with differential expression in BRAFV600E vs NRASQ61R melanoma cells. We selected, 
for comparison, a peculiar model based on melanoma clones, isolated from a single 
tumor characterized by mutually exclusive expression of BRAFV600E and NRASQ61R in 
different cells. This effort led us to identify two genes, SEMA6A and MICAL1, highly 
expressed in BRAF-mutant vs NRAS-mutant clones. Real-time PCR, Western blot and 
immunohistochemistry confirmed preferential expression of Sema6A and Mical1 in 
BRAFV600E melanoma. Sema6A is a member of the semaphorin family, and it complexes 
with the plexins to regulate actin cytoskeleton, motility and cell proliferation. Silencing 
of Sema6A in BRAF-mutant cells caused cytoskeletal remodeling, and loss of stress 
fibers, that in turn induced cell death. Furthermore, Sema6A depletion caused loss of 
anchorage-independent growth, inhibition of chemotaxis and invasion. Forced Sema6A 
overexpression, in NRASQ61R clones, induced anchorage-independent growth, and a 
significant increase of invasiveness. Mical1, that links Sema/PlexinA signaling, is also 
a negative regulator of apoptosis. Indeed, Mical-1 depletion in BRAF mutant cells 
restored MST-1-dependent NDR phosphorylation and promoted a rapid and massive 
NDR-dependent apoptosis. Overall, our data suggest that Sema6A and Mical1 may 
represent new potential therapeutic targets in BRAFV600E melanoma. 
INTRODUCTION
The development of mutant BRAF and of MEK1/2 
inhibitors has markedly improved treatment of advanced 
BRAF-mutant melanoma [1-2] showing highly significant 
effects on progression-free and/or overall survival in 
several phase III trials, in comparison to chemotherapy 
[3]. Nevertheless, a fraction of patients does not benefit 
from target-specific therapy and duration of clinical 
responses can be limited. Intrinsic and acquired resistance 
to small molecule inhibitors limit the efficacy of these 
therapeutic approaches [4-5], highlighting the urgent need 
for identification of new molecules and pathways that 
may contribute to melanoma growth. Several screening 
strategies have been proposed to identify genes with a 
significant role in BRAFV600Emelanoma persistence. These 
include identification of BRAF target genes by comparing 
gene expression profiles in melanomas treated with/
without BRAF inhibitors [7], screening for expression 
of relevant molecules to be targeted by inhibitors [8-11], 
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and comparison of gene expression profiles of BRAFV600E 
vs wild-type tumors [12-13]. The latter approach has the 
advantage of contributing to define the gene expression 
landscape associated with a frequently activated oncogene, 
but conflicting results have been published [14-19] 
possibly due to strong inter-tumor genetic heterogeneity. 
To reduce the impact of this heterogeneity, we exploited 
a set of melanoma clones, isolated from a metastasis 
containing both BRAFV600E and NRASQ61R cells [20]. The 
clones, previously shown to have mutually exclusive 
expression of activated BRAFV600E or NRASQ61R [20], were 
used for whole genome gene expression profiling aimed at 
identifying genes overexpressed in BRAFV600E cells. This 
approach led us to identify the semaphorin SEMA6A, a 
ligand of Plexin A2 and A4 [21-23], as one of the most 
discriminating genes, overexpressed in BRAF-mutant 
clones compared to NRASQ61R clones. Interestingly, 
another gene in the semaphorin-plexin pathway, MICAL1 
(molecule interacting with CasL), that links Sema/PlexinA 
signaling to F-actin disassembly [24-26], showed similar 
differential expression in BRAF-mutants compared to 
NRAS-mutant clones. Although the sema/plexin/mical 
pathway has been thoroughly investigated for its role 
in repulsive guidance, recent studies point to a role of 
its different components in regulating cell survival and 
migratory functions even in neoplastic cells [27]. It 
has been demonstrated that semaphorine 3A regulates 
tumor persistence by suppressing apoptosis triggered 
by plexin D1 dependent receptor [28]. Among this class 
of molecules, Sema6A regulates vascular development 
in tumors and angiogenesis by modulating VEGFR2 
signaling in endothelial cells [22]. Mical1 is a multi-
domain flavoprotein monoxigenase binding NDR1/2 
kinases, thus inhibiting both their phosphorylation by 
MST1 and NDR-mediated apoptosis [26, 29]. We tested 
whether Sema6A and Mical1 could exert a significant pro-
tumoral role in BRAFV600E melanomas by contributing to 
regulate their growth, survival, and invasion. The results 
confirmed this hypothesis and suggested that different 
components of the sema/plexin/mical signaling cascade 
may represent new therapeutic targets in melanoma. 
RESULTS
BRAFV600E and NRASQ61R clones isolated from 
the same metastatic melanoma have distinct 
biological behavior and gene expression profiles
The distinct genetic makeup of BRAF-mutant and 
NRAS- mutant clones derived from the 665/2 cell line 
Figure 1: Sema6A and Mical1 are highly expressed in BRAFV600E compared to NRASQ61R melanoma. (A) Average 
expression of SEMA6A and MICAL1 mRNA examined by qRT-PCR±SD. (B) Total cell lysates from cell line 665/2, from BRAF and 
NRAS clones isolated from 665/2 and from seven BRAF-mutant cell lines were analyzed by WB for expression of Sema6A, Mical1, 
ErbB3, ErbB2, total and pAkt, total and pERK, and Hsp70.
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[20] was associated with different biological behavior 
in vivo. Upon intracardiac injection, BRAFV600E clones 
metastatized in all mice and all organs, except for spleen 
and testis, while only one NRASQ61R clone was able to 
metastasize, and only in one mouse and exclusively to 
the intestine and stomach (Table S1). These marked 
differences were reflected in the gene expression profiles. 
Whole genome microarray analysis of BRAFV600E and 
NRASQ61R clones (Fig. S1) identified SEMA6A as one 
of the most discriminating genes, highly expressed in 
the BRAFV600E clones compared to the NRASQ61R ones. 
Another gene belonging to the sema/plexin signaling 
pathway, MICAL1, was also expressed at significantly 
higher levels in BRAF clones (Fig. S1). Higher expression 
of Sema6A and Mical1, at both RNA and protein levels, 
in BRAFV600E clones, was confirmed by qRT-PCR and 
WB, respectively (Fig. 1A, and B). We also found high 
expression of both Sema6A and Mical1 in BRAFV600E cells 
derived from seven different melanoma cell lines isolated 
from primary tumor or from lymph node metastases 
(Fig. 1B). Most BRAFV600E clones and cell lines in this 
panel showed constitutive activation of the AKT and 
ERK pathway, while NRASQ61R clones showed reduced 
activation of AKT pathway, a finding consistent with the 
lower/missing expression of ErbB2/ErbB3 receptor, the 
strongest activator in nature of PI3K [30]. 
Sema6A and Mical-1 are highly expressed in 
vivo in BRAFV600E tumors compared to wild type 
melanomas and nevi
To assess whether Sema6A and Mical-1 were 
preferentially expressed in BRAFV600E tumors, we analyzed 
their expression by qRT-PCR and immunohistochemistry 
(IHC) on BRAFV600E and BRAF wild type (WT) melanoma 
specimens derived from patients surgically treated at the 
Regina Elena National Cancer Institute. Both molecules 
Figure 2: Sema6A and Mical1 are highly expressed in vivo in B-RAFV600E compared to WT melanomas. (A-B) Expression 
of SEMA6A and MICAL1 mRNA was examined by qRT-PCR on lymph node biopsies from patients carrying BRAFV600E or WT tumors 
(left and right graphs). Representative Sema6A and Mical1 IHC on sections derived from same samples. Secondary antibody was used as 
internal control. Scale bar 30 µm. 
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were also analyzed in nevi. The results demonstrated that 
Sema6A and Mical-1 were significantly more expressed in 
BRAFV600E than in WT melanomas (P<0.02 and P<0.009, 
respectively) (Fig. 2A and B). In nevi, Sema6A and 
Mical-1 expression was comparable to the levels found 
in WT melanoma (Fig. S2). Representative IHC analyses 
with the relative internal controls are reported for both 
molecules in the two subtypes of melanoma (Fig. 2A and 
B) and in nevi (Fig.S2). These data supported our in vitro 
results.
Depletion of Sema6A in BRAF-mutant melanoma 
cells promotes cell death
To investigate the role of Sema6A in BRAFV600E 
cells, we carried out siRNA experiments, with different 
Sema6A-specific silencing sequences (siSema6A) in 
three clones isolated from 665/2 cell line and in one cell 
line (10538) isolated from a BRAFV600E primary tumor. 
Sema6A depletion strongly induced PARP cleavage in 
clone 2/21 and reduced total PARP in the clones 2/56 
and 2/59 and in the melanoma cell line 10538 (Fig. 
3A). Surprisingly, Sema6A silencing inhibited ErbB3 
expression and phosphorylation of AKT, and to a lesser 
extent, of ERK (Fig. 3A). ErbB3 down-regulation was 
likely post-transcriptional, secondary to p-Akt inhibition, 
as previously described [31], and not transcriptional, as 
demonstrated by qRT-PCR (Fig. 3B). The above results 
were confirmed by silencing of Sema6A by a second 
specific siSema6A sequence (Fig. S3A), and even by a 
third specific commercially available siSema6A (data 
not shown). Interestingly, PI3K and MAPK activity 
appeared to be regulated downstream of Sema6A, as 
their phosphorylation levels (Fig. 3A, and S3A) clearly 
correlated with Sema6A depletion, suggesting that this 
semaphorin can regulate major pathways supporting 
melanoma cell viability. To further explore this possibility, 
Figure 3: Interference for Sema6A induces cells death, and inhibits PI3K pathway. (A) siSema6A/BRAFV600E clones and 
primary melanoma cell line 10538 were analyzed by WB for expression of Sema6A, ErbB-3, ErbB-2, P-AKT, P-ERK1/2, PARP, and 
Hsp70. (B) Average expression of ErbB-3 mRNA examined by qRT-PCR±SD in Control, siScr, and siSema6A in clone 2/59. (C) Cell death 
of siSema6A/BRAFV600E cells was evaluated at 48 h post-transfection by Trypan blue exclusion from three independent experiments; bars 
± S.D. 
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we carried out apoptosis assays by FACS analysis. 
Annexin-V/PI staining assays indicated that Sema6A 
depletion induced apoptosis, associated with caspase 
3/7 activation, in BRAFV600E clones 2/56 and 2/59 and in 
melanoma cell line 10538, with effects already evident at 
24-36h (Fig. S4). Trypan blue exclusion assays confirmed 
that siSema6A induced death in all cells tested compared 
to controls or siScr transfected cells (Fig. 3C). Taken 
together these results suggested that Sema6A promotes 
survival of BRAF-mutant melanoma cells.
Depletion of Sema6A in BRAF-mutant melanoma 
cells alters the cytoskeleton and impairs 
anchorage-independent growth, as well as motility 
and invasive activities
Sema6A silencing led to down-regulation of 
Caspase 3 and reduction of total PARP when cells where 
plated on conventional cell culture dishes, but not on 
Fibronectin-coated dishes suggesting cell death by loss of 
cell adhesion (Fig. 4A). The Cell death was confirmed by 
TUNEL assays showing fragmentation of nuclei only in 
Figure 4: Interference with Sema6A expression in BRAF 2/59 cells induces cytoskeletal remodeling and inhibits 
anchorage-independent growth. (A) Control, siScr- or siSema6A/BRAFV600E cells were plated onto FN coated-dish or conventional 
culture-dish. Total cell lysates were analyzed by WB with PARP, Caspase3, and Hsp70 antibodies. (B) Tunel assay of BRAF/siSema6A 
cells plated on FN and/or poli-lysine. (C) Histogram reported percentage of tunel positive cells (P<0.004). (D) The cells, 48 h post-
transfection, were plated on poly-l lysine coated slides, and stained with phalloidin-TRITC to show actin filaments. Scale bar is 10 µm. (E) 
Histogram reported percentage of stress fiber positive-cells. (F) Ctrl, siScr and siSema6A/BRAFV600E cells soft agar assay. (G) Histogram 
reported the number of colonies obtained in soft agar assay in Ctrl, siScr and siSema6A cells. 
Oncotarget2784www.impactjournals.com/oncotarget
siSema6A cells plated on poli-lysine (Fig. 4B). Graphical 
representation of percentage of TUNEL positive cells is 
reported in Figure 4C (P<0.004). Silencing of Sema6A 
also induced changes in the actin cytoskeleton as shown 
by loss of actin stress fibers consistent with impaired cell 
adhesion and with promotion of cell death by anoikis 
(Fig. 4D, and E, P<0.0001). These results were further 
confirmed in clones 2/56, 2/21, and in 10538 cell line (Fig. 
S5A and B, right panels). These changes were not observed 
in untreated or siScr/cells (Fig. 4D, and E, and Fig. S5A 
and B, left and central panels). These results suggested 
that Sema6A might contribute to anchorage-independent 
growth of BRAFV600E melanoma cells. Indeed, Sema6A 
depletion strongly suppressed growth of BRAFV600E cells 
in soft agar (Fig. 4F, and G). siSema6A cells formed very 
small colonies appearing later, compared to control or to 
siScr/cells (P<0.0001) confirming that Sema6A controls 
anchorage-independent growth. In agreement with above 
results, Sema6A depletion in BRAF mutant cells strongly 
reduced their capability to migrate and to invade in vitro 
(P≤0.001) (Fig. S6A and B, upper and lower panels).
Ectopic expression of Sema6A in NRAS-mutant 
cells promotes in vitro and in vivo invasion
We then tested whether forced overexpression of 
Sema6A in NRASQ61R clones could promote anchorage-
independent growth and invasiveness. In contrast with 
in vivo results on development of metastases (Table S1) 
and with data indicating that NRAS mutant clones yield 
only small colonies in soft agar [20], we found that 
overexpression of Sema6A in NRASQ61R melanoma clones 
Figure 5: Sema6A controls invasion. (A) Overexpression of Sema6A by WB (upper part of the figure), and invasion assay (lower 
part of the figure), and (B) soft agar assay, of control and Sema6A/NRASQ61R overexpressing clones (2/14 and 2/17). (C) Box plot of in vivo 
skeletal tissues metastases analysis was obtained by software Prism version 6.0. 
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conferred a strong invasive activity in vitro (P≤0.0001) 
(Fig. 5A), and capability to generate large colonies in 
soft agar (P≤0.02) (Fig. 5B). Furthermore, depletion of 
Sema6A in NRASQ61R melanoma clones down-regulated 
their capability to invade (P≤0.001) (Fig. S7). More 
importantly, by in vivo assessment for metastatic ability 
of NRAS-mutant cells overexpressing Sema6A, we found 
that several components of the skeletal system of the mice 
(spinal column, femurs, and upper and lower limbs) were 
characterized by presence of metastatic foci. Moreover, we 
found a significant increase, at these anatomical sites, in 
the fraction of tissue being interested by metastatic foci, 
compared to tissues from mice receiving control NRAS-
mutant cells (Fig. 5C). Analysis of additional organs 
(Table S2) demonstrated that NRAS cells overexpresing 
Sema6A frequently produced metastases also in the 
brain, lung, pancreas and heart, compared to control cells. 
These data strongly support the role of Sema6A in the 
mechanisms that promote melanoma invasion. 
Sema6A functions in BRAF-mutant melanoma 
cells are independent from PlexinA2 and PlexinA4 
receptors
We then looked at expression and function in 
melanoma cells of Plexin-A2 and Plexin-A4, the Sema6A 
receptors. In agreement with previous results [32], all 
BRAFV600E clones and cell lines expressed heterogeneous 
levels of Plexin-A4 (Fig. S8A, and B) compared to the 
level found for Sema6A (Fig. 1), while all clones and cell 
lines were negative for the expression of Plexin-A2 (data 
not shown). Both PlexinA4 and PlexinA2 were absent in 
NRASQ61R clones (Fig. S8A and B, and data not shown). 
Surprisingly, depletion of Plexin-A4 in BRAFV600E clone 
by siRNA did not induce cell death and did not alter the 
actin cytoskeleton (data not shown). Silencing of both 
molecules led to the expected changes already found 
upon siSema6A alone (Fig. S8C). Taken together these 
results suggest that Sema6A and Plexin-A4 have distinct 
roles in regulating biological functions in BRAF-mutant 
melanoma cells. 
Mical1 depletion induces melanoma cell death by 
apoptosis
Mical1 is a mediator of Sema/Plexin repulsion, and 
acts by promoting F-actin disassembly [33-34]. Mical1 
enhanced expression in BRAFV600E clones, and its known 
role as an effector of the Sema/Plexin axis, suggested 
that it could exert functions similar to those regulated by 
Sema6A. To address this possibility we depleted Mical1 
by siRNA. Surprisingly, Mical1 silencing did not change 
the actin cytoskeleton organization, indicating that its role 
in BRAFV600E melanoma cells is not overlapping with that 
of Sema6A. A candidate function for Mical1 is interaction 
with NDR, a pro-apoptotic kinase, antagonizing MST1-
induced NDR phosphorylation to trigger apoptosis [29]. 
Indeed, silencing of Mical1 in BRAFV600E melanoma 
clones (2/59, 2/56) and in 10538 melanoma cell line caused 
strong NDR phosphorylation between 30 h and 36 h post 
transfection associated with PARP cleavage (Fig. 6A). By 
Annexin-V/PI flow cytometry assay, we also found that 
Mical1 depletion in these melanoma cells increased both 
early (annexin-V+PI-) and late (Annexin-V+PI+) apoptosis, 
compared with the effects seen in cells transfected with 
control siRNA (siScr, Fig. 6B), suggesting that Mical-1 
protects BRAFV600E melanomas from apoptosis. These 
results were confirmed by the use of a second siMical1 
(Fig. S3B), and by a commercially available siMical1 
(data not shown). By caspase-3 activation assays on the 
same cells, we confirmed that siMical1 induced melanoma 
apoptosis (Figure 7A, B). Analysis for phosphorylation 
of H2B-S14, that co-localizes with Hoechst positivity 
in fragmented nuclei, further supported the evidence 
that siMical1 induces apoptosis in BRAFV600E melanoma 
without affecting the actin cytoskeleton (Fig. 7C, D). 
Taken together, these results support the notion that both 
Sema6A and Mical1 promote cell survival, and inhibit 
cell death of BRAFV600E melanomas through different 
pathways. 
DISCUSSION
In attempts to find molecules regulating 
aggressiveness of BRAFV600E melanoma cells, by whole-
genome array we found that SEMA6A and MICAL1, 
two genes of the SEMA/PLEXIN signaling pathway, 
were over-expressed in BRAFV600E clones compared to 
NRASQ61R clones isolated from the same metastasis. In 
vitro and in vivo assays confirmed the selective expression 
of the corresponding proteins in BRAFV600E cell lines 
derived from primary and metastatic melanoma lesions 
or in BRAF mutant tumors compared to BRAF wild type 
tumors and nevi. Sema6A belongs to a large family of 
secreted or trans-membrane proteins and its receptors are 
PlexinA2 and PlexinA4. Sema6A/Plexin complexes were 
previously characterized for their role in vascular and 
neural development [22]. However a role of SEMA6A in 
cell proliferation, survival, anchorage-independent cell 
growth, and invasion of BRAFV600E melanoma was not 
previously described. We found that Sema6A-depletion 
in BRAFV600E clones and primary tumor cells results 
in cell death. Specifically, Sema6A depletion reduces 
Akt phosphorylation and suppresses ErbB-3 expression 
suggesting that its inhibition of cell proliferation could 
depend on loss of ErbB-2/ErbB-3 heterodimer formation. 
Loss of Sema6A by siRNA caused a very low reduction 
of ErbB-2 expression and of ERK activity suggesting that 
in these cells ErbB-2 homodimer may still contribute to 
cell proliferation. However, when the cells were forced 
to adhere to fibronectin (FN) we did not find cleavage of 
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Figure 6: Silencing Mical1 induces apoptosis. (A) siMical-1/BRAFV600E cell lysates from 2/59 and 2/56 clones, and 10538 primary 
tumor were analyzed at the indicated time post-transfection for expression of Mical1, total and pNDR, and PARP. (B) Apoptosis was 
evaluated by Annexin-V/PI flow cytometric assay.
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Figure 7: Silencing Mical1 induces Caspase 3/7 activation and H2B phosphorylation on Serine 14. (A) siMical-1/
BRAFV600Ecells were analyzed with Muse™ Caspase-3/7 assay. (B) Caspase-3/7 activity after transfection with siScr (black bars) or 
siMICAL1 (white bars) is reported. (C) Cells plated on poly-l lysine coated slides, stained with phalloidin-TRITC, and anti-H2B-pS14 
that co-stains with Hoechst of apoptotic nuclei of siMical-1/BRAFV600E cells. (D) Scale bar is 10 µm. Histogram reported the percentage of 
H2B-pS14 positive cells.
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PARP and activation of caspase 3. 
Previous studies have shown that depletion of 
Sema6A in endothelial cells reduces VEGFR2 expression 
and abolish its phosphorylation, thus inducing cell death. 
Interestingly, stimulation by VEGF did not restore cell 
proliferation in Sema6A-depleted endothelial cells, 
demonstrating that Sema6A mainly control proliferation 
through the VEFGR2 receptor [22]. Overall, the results 
of this study add further evidence for a direct role of 
SEMA6A as regulator of cell proliferation even in 
neoplastic cells. 
Cells with depleted Sema6A showed loss of stress 
fiber and actin distribution exclusively under the cell 
membrane. This was associated with loss of adhesion 
to the substrate, reduced growth in soft agar, inhibition 
of chemotaxis and invasion. In agreement, there are 
several evidences demonstrating that semaphorins 
control the adhesion regulating integrin function in 
vascular morphogenesis and cancer progression [35-36]. 
In particular, it has been shown that Sema3A impairs 
endothelial cell adhesion and migration by inhibiting 
integrin activation [35]. In contrast but in agreement with 
our data, Sema3C promotes endothelial cell adhesion and 
migration by increasing integrin activity [36]. It is also 
been described that neuropilins interacting with numerous 
growth factors receptor and semaphorins promote tumor 
progression [37]. All these data suggest the complexity 
of Semaphorins functions and that there is much still to 
be learned about their involvement in tumor initiation, 
growth, and metastatization.
Our study demonstrated strong capability of 
BRAFV600E clones to metastazise in mice, and in agreement 
with previous results [20], to form high number of big 
colonies in soft agar compared to NRASQ61R clones. 
These data were further confirmed by the strong acquired 
capability of NRASQ61R clones, overexpressing Sema6A, 
to grow in soft agar and to metastasize in vitro and in vivo 
suggesting a specific role of Sema6A regulating tumor 
progression. These finding are strongly in agreement 
with previous study showing that Sema6A represents, 
in melanoma cell line M14, one of the major modulated 
genes in response to MAPK inhibitor PD0325901 [38] 
and with our data showing that Vemurafenib treatment 
increases Sema6A expression in vemurafenib-resistant 
cells but inhibits Sema6A expression in the vemurafenib-
responsive cells (unpublished data). 
PlexinA2 and PlexinA4, known Sema6A receptors 
[39-40], showed differential expression in BRAF-mutant 
clones and melanomas, indicating that in such tumors only 
Plexin-A4 acted as Sema6A receptor. We hypothesized 
that depletion of Plexin-A4 may recapitulate the effects of 
Sema6A silencing. However, PlexinA4 silencing did not 
induce any of the effects of Sema6A depletion, suggesting 
that other, as yet unidentified, receptors could be involved. 
This result is in agreement with the finding that Sema6A 
regulates angiogenesis by a mechanism that is PlexinA2- 
and PlexinA4-independent [22]. 
The other Sema/Plexin pathway-related molecule 
we found highly expressed in BRAFV600E cells and tumors 
compared to NRASQ61R cells, WT tumors and nevi, is 
MIical1. In vertebrates, this molecule interact with class 
A Plexins [41], suggesting that it could be a mediator of 
Sema6A signaling in melanoma cells. However, MICAL1 
silencing, as well as PlexinA4, did not produce the same 
effects as Sema6A depletion. Specifically, we observed 
early and massive cell death by apoptosis in all cell lines 
tested suggesting that Mical1 plays a Sema6A-independent 
role in these tumors. These results are in agreement with 
the finding that Mical1 control cell survival by binding 
to the phosphorylation site of NDR, that in turn inhibits 
NDR phosphorylation-dependent apoptosis [29]. Indeed, 
Mical-1 depletion induced NDR phosphorylation and cell 
death by apoptosis. 
In conclusion our results revealed that BRAFV600E 
melanomas express high level of Sema6A and MICAL1 
whose functions are strongly involved in the mechanisms 
that control cell proliferation and survival. Our results 
strongly support the hypothesis that both molecules could 
represent new potentially relevant therapeutic targets in 
BRAFV600E melanoma as emerging from recent literature 
[41-42]. 
METHODS
Cell lines and Transfection 
BRAFV600E melanoma cell lines were derived from 
primary tumor (10538), from lymph node metastases 
(4686, 4023, 18732, 18656, 15392, 14464), and from s.c. 
665/2 metastasis. All melanoma cell lines were isolated 
from surgical specimens of melanoma patients, not 
previously subjected to chemotherapy and admitted to 
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. 
All lesions were histologically confirmed to be cutaneous 
malignant melanomas [20, 43-45]. From the parental 
cell line 665/2 (P), which was previously shown to be a 
heterogeneous tumor consisting of BRAF- as well as of 
NRAS-mutant cells (46, 20), several BRAFV600E clones 
(2/21, 2/33, 2/56, 2/59) or NRASQ61R clones (2/4, 2/14, 
2/17, 2/51) were established as described (46). Selection 
of clones for the study was based on the intention to 
select those with the most known and relevant phenotypic 
differences, as previously described [20, 46-48]. 
The study was conducted according to the 
Declaration of Helsinki Principles, and following 
institutional guidelines. Molecular and biological features 
of the cell lines and clones, are described in refs [20, 43, 
46]. Methods for identification of mutations in BRAF and 
NRAS have been previously reported [20, 43].
BRAFV600E clones and primary tumor 10538, were 
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depleted for Sem6A, Mical1, and PlexinA4 expression 
with specific siRNA (siSema6A, siMical1, siPlexinA4) 
or scramble (siScr) as described [49]. The siRNAs were 
either generated by Silencer® siRNA construction kit 
(Ambion, Glasgow, UK) or purchased from Origene or 
Life Technlogies.
Template oligonucleotides sequences were:
SEMA6A-5’AAATAGTCGCGGCGACTACTTCC
TGTCTC3’ 
5’AAAAGTAGTCGCCGCGACTATCCTGTCTC3’ 
SEMA6A (2): AS: 5’- 
AAGCCTTGCTGCTATATTTCACCTGTCTC – 3’
S: 5’ – 
AATGAAATATAGCAGCAAGGCCCTGTCTC – 3’
SEMA6A (3): Life Technologies, Code N. 
AM16708
MICAL1-5’AAGGACGTCAAATTCATAGTTCC
TGTCTC3’ 
5’AAAACTATGAATTTGACGTCCCCTGTCTC3’
MICAL1 (2):AS: 5’- 
AACTACTGGAGCGCCAAGTCACCTGTCTC – 3’
S: 5’- 
AATGACTTGGCGCTCCAGTAGCCTGTCTC – 3’
MICAL1(3): Origene, Code N. SR312119
PLEXINA4-
5’AAGCAGCGGTCATTTGTCACACCTGTCTC 3’
5’AATGTGACAAATGACCGCTGCCCTGTCTC 
3’
Scr1-5’AAGCGCAACTCTACCTCTACCTGTC
TC3’ 
5’AATAGAGGTAGAGTTGCGCGCCCTG 
TCTC3’
Scr2-5’AATAGAGGTAGAGTTGCGCGCCCTGT
CTC3’
 5’AAGCGCGCAACTCTACCTCTACCTGTCTC3’
Antibodies 
Anti-Sema6A and anti-Mical1 (SIGMA-Aldrich, 
MO, USA), anti-total and phospho-ser473-Akt, anti-
total and phospho-ERK 1/2, and anti-PARP were from 
Cell Signaling (Milan, Italy), anti-ErbB-2, anti-ErbB-3, 
anti-Caspase 3, and anti-Hsp-70 (Oncogene, MA, USA), 
(Santa Cruz Biotechnology, CA, USA), and (Stressgen, 
NY, USA), anti-phospho-NDR(Thr444) was provided 
by Dr. Brian Hemmings (Friedrich Miescher Institute 
for Biomedical Research, Basel), anti-total NDR and 
anti-phospho-H2B-S14, and HRP-conjugated secondary 
antibodies were from (Millipore, Billerica, MA, USA), 
and (Bio-Rad, CA, USA). For IHC, the secondary 
antibody was used as internal control.
Western Blots 
Clones and cell lines, before and after transfection, 
were lysed, analyzed by SDS-PAGE and probed (WB) 
with antibodies of interest and secondary HRP-conjugated 
antibodies [49]. Signals were detected by LuminataTM 
Classico Western HRP substrate (Millipore). Same amount 
of total protein from three independent experiments were 
pooled and analyzed. 
In vivo experiments 
CD-1 male nude (nu/nu) mice, 6–8 weeks old and 
weighing 22-24 g were purchased from Charles River 
Laboratories (Calco, Italy). The procedures involving 
mice were in compliance with Regina Elena National 
Cancer Institute animal care guidelines and with national 
and international directives (D.L. March 4, 2014, no. 26; 
directive 2010/63/EU of the European parliament and of 
the council; Guide for the Care and Use of Laboratory 
Animals, United States National Research Council, 2011).
For the intracardiac experimental metastasis model, 
nude mice (age 8–10 weeks) were anesthetized and 
injected with 2x106 cells of NRASQ61L (2/14, 2/17) or 
BRAFV600E (2/21, 2/33) clones, suspended in 100 μl sterile 
PBS, into the left ventricle of the heart by nonsurgical 
means. The spontaneous, pulsatile entrance of bright 
red oxygenated blood into the transparent needle hub 
indicated proper positioning of the needle. After 5 weeks, 
the mice were sacrificed; selected organs were excised 
from the mice at necropsy and were preserved in 10% 
formalin solution for subsequent scoring of metastasis. 
NRASQ61L (2/14, 2/17) and NRAS/Sema6A cells (2/14, and 
2/17) were injected intracardially as above described, and 
after 7 weeks the mice were sacrificed and the organs were 
processed and analyzed as described above. Box plot of in 
vivo metastasis analysis was obtained by software Prism 
version 6.0.
Gene expression profiles 
Gene expression profiles of BRAFV600E and 
NRASQ61R melanoma clones isolated from 665/2 cell 
line were assessed as described [44].Three biological 
replicates of each clone were analyzed. Single-color 
hybridization of RNAs was performed on Illumina 
Bead Chip HumanHT-12_v4 Microarrays (Illumina) 
containing more than 48,000 transcript probes. The 
expression profiles have been deposited in NCBI’s Gene 
Expression Omnibus (GEO) with GSE accession number 
GSE58199. Background correction, filtering of data, 
and quantile normalization were done with BeadStudio 
Illumina software. Analysis for differentially expressed 
genes was carried out by BRB-array Tools (Vers.4.3.0) 
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software. Class comparison was carried out by a random-
variance F-test with a nominal significance level of 0.001. 
Permutation P values for significant genes were computed 
based on 10,000 random permutations.
Quantitative RT-PCR 
Total RNA from NRASQ61R and BRAFV600E clones 
was prepared using TRIzol® (Ambion). First-strand cDNA 
was synthesized with the M-MLV RT kit (Invitrogen, 
Glasgow, UK). Human tissue samples were obtained from 
the Regina Elena National Cancer Institute, after approval 
by the institutional ethic committee. Total RNA, derived 
from nevi, BRAFV600E and wild type (WT) melanoma, 
was isolated by PureLink FFPE kit (Invitrogen), and 
reverse-transcribed using PrimeScript RT reagent kit 
(Takara). Quantitative PCR (qPCR) was performed using 
SYBR Green on an ABI Prism 7500 apparatus (Applied 
Biosystems, Glasgow, UK) in 2 independent experiments 
in triplicate. The comparative threshold (∆Ct) method was 
used. 
Primer sequences were: 
SEMA6A-Fw-
5’ACAATTCCTTTGTGGCACTGAA, 
Rev5’TCTTGAGCCGTGGAATCTGA
MICAL1-Fw-5’ATGGGCAGCCTGATGTCTCT, 
Rev5’GGCGCCATGCTTCTCTTG
PLEXINA4-Fw-5’TGGCTCAGGCGACCC, 
Rev5’GACGGAGATATTGTTGGGATG
HER3-Fw5’GCAGGATTGGTAGTGATTTTCATG,
Rev-5’TATCGCCTCATAGCCCTTTTATTC
GAPDH-Fw-5’TCCCTGAGCTGAACGGGAAG, 
Rev5’-GGAGGAGTGGGTGTCGCTGT
Immunohistochemistry 
Formalin-fixed paraffin-embedded sections from 
melanoma lymph node metastases of patients treated at the 
Regina Elena National Cancer Institute (53 BRAFV600E 
melanomas, 43 BRAF WT, and 8 nevi) were analyzed 
as described [42]. Antigen retrieval was performed at 
96°C (10 mM/L citrate buffer, pH 6) for 20 minutes. 
Sections were incubated with the primary antibody anti-
Mical-1 1:100 (Sigma Prestige), anti-SEMA6A 1:50 
(Sigma Prestige) for 30 minutes at room temperature. 
Immunoreactions were revealed by Bond Polymer Refine 
Detection Kit according to manufacturer’s procedure 
(Leica Biosystems) in an automated autostainer Bond 
III Leica Biosystems. Diaminobenzidine was used as 
chromogenic substrate. Microscope Nikon ECLIPSE 55i 
with digital camera HESP Tecnology was used. Scale 
bars 30 µm. The study was reviewed and approved by 
the ethical committee of Regina Elena National Cancer 
Institute, and informed consent was obtained from all 
patients.
Cell adhesion, Immunofluorescence, Invasion and 
chemotaxis assays 
siSema6A, and siScr/BRAFV600E cells, 24 hours 
post-transfection were plated onto fibronectin (FN)-coated 
dishes (20 µg/ml, SIGMA-Aldrich), or culture dishes or 
poly-l lysine coated slides and 24 hours later analyzed by 
immunofluorescence. The cells incubated with Phalloidin-
Tetramethylrhodamine B isothiocyanate (TRITC) were 
counterstained with Hoechst to highlight nuclei (SIGMA-
Aldrich). For Tunel assay, siSema6A, and siScr/BRAFV600E 
cells, 24 hours post-transfection were plated onto FN-
coated or poly-l lysine coated slides, as above described. 
48 hours post-transfection TUNEL assay was performed 
following manufacturer’s instructions (Millipore). 
Microscope OLYMPUS BX53 was used to evaluate 
fluorescence and Tunel. Scale bars 20 µm. NRAS/Sema6A 
cells chemoinvasion was assessed as described [49] by 
overexpression of pUSENMC-Sema6A expression vector, 
kindly provided by Silvia Prislei (University Cattolica, 
Rome) [50]. Chemoinvasion or chemotaxis assays after 
depletion of Sema6A in BRAF and NRAS mutant cells, 
were performed as previously described [49]. Each assay 
was carried out in quadruplicate and repeated at least three 
times. 
Soft agar assay 
siSema6A, siScr/BRAFV600E, and Sema6A/NRASQ61R 
cells were transfected and 48 hours later cells (5×103) were 
plated onto 0.4% agar. After 2 weeks viable colonies were 
counted [42] by the software ImageJ 1.47v (NHI, USA). 
Cell death, apoptosis, and caspase activity 
siMical1-, siSema6A-, and siScr/BRAFV600E cells 
were plated at concentration of 4 × 105. After 30, and 36 
hours cell vitality was evaluated by Trypan blue exclusion. 
Apoptosis was assessed by staining with FITC-conjugated 
Annexin-V and Propidium Iodide (BD Pharmingen, BD 
Biosciences San Diego, CA). The samples were acquired 
by FACSCalibur flow cytometer (BD). Enzymatic activity 
of caspases-3/7 was measured with Muse™ Caspase-3/7 
Assay Kit and read by Muse™ Cell Analyzer (Millipore). 
Statistical analysis 
Data were reported as mean and standard deviation 
. Differences were considered statistically significant 
when P≤0.05. All analyses were performed using SPSS, 
version 17.0 (SPSS, Chicago, Illinois). Student T test was 
performed for the comparison of results from qRT-PCR 
and from all other different test (*P<0.05, **P<0.001, 
***P<0.0001). 
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